140 related articles for article (PubMed ID: 16540945)
1. Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?
Furtek KJ; Crum NF; Olson PE; Wallace MR
J Acquir Immune Defic Syndr; 2006 Mar; 41(3):394-6. PubMed ID: 16540945
[No Abstract] [Full Text] [Related]
2. Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir.
Guiard-Schmid JB; Poirier JM; Bonnard P; Meynard JL
J Acquir Immune Defic Syndr; 2006 Mar; 41(3):393-4; author reply 394. PubMed ID: 16540944
[No Abstract] [Full Text] [Related]
3. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.
Zhu L; Persson A; Mahnke L; Eley T; Li T; Xu X; Agarwala S; Dragone J; Bertz R
J Clin Pharmacol; 2011 Mar; 51(3):368-77. PubMed ID: 20457590
[TBL] [Abstract][Full Text] [Related]
4. Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and saquinavir.
López Galera RM; Ribera Pascuet E; Esteban Mur JI; Montoro Ronsano JB; Juárez Giménez JC
Eur J Clin Pharmacol; 2008 Dec; 64(12):1235-6. PubMed ID: 18712519
[No Abstract] [Full Text] [Related]
5. Review of atazanavir: a novel HIV protease inhibitor.
Fuster D; Clotet B
Expert Opin Pharmacother; 2005 Aug; 6(9):1565-72. PubMed ID: 16086644
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Le Tiec C; Barrail A; Goujard C; Taburet AM
Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir.
Manosuthi W; Sungkanuparph S; Ruxrungtham K; Prasithsirikul W; Athichathanabadi C; Tantisiriwat W; Bowonwatanuwong C; Chumpathat N; Chaovavanich A
J Acquir Immune Defic Syndr; 2008 Jan; 47(1):127-9. PubMed ID: 18156994
[No Abstract] [Full Text] [Related]
8. Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Atazanavir--booster of the future?
TreatmentUpdate; 2003; 15(3):5-6. PubMed ID: 17219613
[No Abstract] [Full Text] [Related]
9. Lack of interaction between atazanavir and lansoprazole.
Kosel BW; Storey SS; Collier AC
AIDS; 2005 Mar; 19(6):637-8. PubMed ID: 15802988
[No Abstract] [Full Text] [Related]
10. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
[TBL] [Abstract][Full Text] [Related]
11. Co-administration of atazanavir with proton-pump inhibitors and H2 blockers.
Khanlou H; Farthing C
J Acquir Immune Defic Syndr; 2005 Aug; 39(4):503. PubMed ID: 16010179
[No Abstract] [Full Text] [Related]
12. Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.
Di Biagio A; Rosso R; Loregian A; Pagni S; Sormani MP; Cenderello G; Palù G; Viscoli C
J Infect Chemother; 2012 Aug; 18(4):587-90. PubMed ID: 22422300
[TBL] [Abstract][Full Text] [Related]
13. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
[TBL] [Abstract][Full Text] [Related]
14. PI monotherapy effective as maintenance.
AIDS Patient Care STDS; 2005 Oct; 19(10):696. PubMed ID: 16232054
[No Abstract] [Full Text] [Related]
15. Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen.
von Hentig N; Kaykhin P; Stephan C; Babacan E; Stürmer M; Staszewski S; Lötsch J
Antimicrob Agents Chemother; 2008 Jun; 52(6):2273-5. PubMed ID: 18411323
[TBL] [Abstract][Full Text] [Related]
16. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.
Karlström O; Josephson F; Sönnerborg A
J Acquir Immune Defic Syndr; 2007 Apr; 44(4):417-22. PubMed ID: 17159658
[TBL] [Abstract][Full Text] [Related]
17. Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir.
DiCenzo R; Peterson DR; Cruttenden K; Mariuz P; Rezk NL; Hochreiter J; Gelbard H; Schifitto G
Antimicrob Agents Chemother; 2008 Sep; 52(9):3035-9. PubMed ID: 18573930
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens.
Regazzi M; Villani P; Gulminetti R; Cusato M; Brandolini M; Tinelli C; Barassi A; Maserati R; Sighinolfi L; D'Arminio Monforte A; Melzi D'Eril GV
Ther Drug Monit; 2011 Jun; 33(3):303-8. PubMed ID: 21544015
[TBL] [Abstract][Full Text] [Related]
19. Atazanavir: in pediatric patients with HIV-1 infection.
Deeks ED
Paediatr Drugs; 2012 Apr; 14(2):131-41. PubMed ID: 22292486
[TBL] [Abstract][Full Text] [Related]
20. Drug interactions. Kaletra and atazanavir.
TreatmentUpdate; 2006; 18(3):7-8. PubMed ID: 17211919
[No Abstract] [Full Text] [Related]
[Next] [New Search]
